lonapegsomatropin
Stories
-
Ascendis Pharma registers Phase 3 trial of navepegritide and lonapegsomatropin in achondroplasia
The study, led by Ascendis Pharma A/S, plans to enroll 144 participants and start in November 2026. It compares dual therapy with navepegritide and lonapegsomatropin to navepegritide monotherapy and lonapegsomatropin monotherapy in children and adolescents with achondroplasia.